Foresight Diagnostics specializes in advanced cancer diagnostics through its innovative Foresight CLARITY™ platform, which utilizes proprietary PhasED-Seq™ technology. This platform is designed to detect minimal residual disease (MRD) from circulating tumor DNA (ctDNA) with exceptional sensitivity, enabling the identification of disease recurrence much earlier than traditional imaging methods like PET/CT. By tracking unique genomic differences between cancerous and healthy cells, Foresight CLARITY™ can detect ctDNA levels below one part per million, significantly enhancing the accuracy of cancer diagnostics. This capability allows clinicians to make timely and informed decisions throughout the patient treatment journey, potentially improving clinical outcomes.

The technology not only aids in early relapse detection but also supports personalized treatment strategies by allowing for mid-therapy adjustments based on ctDNA levels. Foresight Diagnostics collaborates with various academic and biopharma partners to explore the clinical applications of MRD detection, demonstrating its effectiveness across multiple cancer types. The platform's ability to provide actionable data at critical points in treatment positions it as a transformative tool in oncology, paving the way for more effective cancer management and drug development.

United States

Foresight Diagnostics is a precision medicine company developing a novel liquid biopsy test for the measurement of minimal residual disease (MRD) for aid in patient management that is funded by leading diagnostics VC firms in Silicon Valley. Foresight’s cell-free DNA testing platform was developed in the labs of two prominent professors at Stanford University and is backed by several major peer-reviewed publications. The company has garnered significant partnering interest from multiple pharmaceutical companies in oncology and is poised for rapid growth. Foresight Diagnostics is headquartered in Aurora, Colorado.

Foresight Diagnostics

Company Details